Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 25, 2025Frontiers in Aging NeuroscienceOpen Access

GLP-1R as a potential link between diabetes and Alzheimer’s disease

View Full Paper
Ask AI
Bookmark
Share

Authors

SLShujun LiNHNanqu HuangMWMei Wang

Discussion

Loading...

Member takes

Overview

This analysis reveals GLP-1R impacts insulin signaling in diabetes and reduces amyloid-beta in Alzheimer’s disease, suggesting a critical connection.

Key Points

  • GLP-1R is pivotal in regulating glycemic control, affecting insulin secretion and lowering blood glucose in diabetes.
  • In Alzheimer’s disease, GLP-1R mitigates pathological features by reducing amyloid-beta deposition and enhancing clearance.
  • Both diabetes and Alzheimer’s disease share disrupted insulin signaling pathways, highlighting their interconnectedness.
  • Future investigations should focus on GLP-1R's mechanisms and the potential of GLP-1R agonists for dual therapies.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/689a0627e6551bb0af8ce272https://doi.org/10.3389/fnagi.2025.1601602
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Potential Role of GLP-1 Receptor Agonists for the Treatment of Alzheimer's Disease2025
  2. 2Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment2022 · 287 citations
  3. 3The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials2025
  4. 4GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential2025 · 28 citations
  5. 5The Association of Circulating Glucagon-Like Peptide-1 with Cognitive Functions and Biomarkers in Alzheimer’s Disease2024 · 2 citations